Literature DB >> 29184474

Neoadjuvant Strategies: Locally Advanced Rectal Cancer.

Shahab Ahmed1, Cathy Eng1.   

Abstract

Colorectal cancer is one of the major leading causes of death in both men and women. The successful management of colon or rectal cancer demands a multidisciplinary approach. In the last few years, significant improvement has been noticed in the management of localized rectal cancer to reduce local recurrence and obtain complete pathological response following appropriate surgical steps, if necessary. Implementation of neoadjuvant therapy not only enhances disease control, it may also ensure sphincter preserving procedures or organ-preserving options. This article principally concentrates on the current neoadjuvant treatment for locally advanced rectal cancer and the prognostic outcomes of such therapy, including a discussion on the historical perspective.

Entities:  

Keywords:  adjuvant chemotherapy; colorectal cancer; neoadjuvant chemoradiation; rectal cancer; survival

Year:  2017        PMID: 29184474      PMCID: PMC5703667          DOI: 10.1055/s-0037-1606372

Source DB:  PubMed          Journal:  Clin Colon Rectal Surg        ISSN: 1530-9681


  19 in total

1.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

Authors:  E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

2.  Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate.

Authors:  Joakim Folkesson; Helgi Birgisson; Lars Pahlman; Bjorn Cedermark; Bengt Glimelius; Ulf Gunnarsson
Journal:  J Clin Oncol       Date:  2005-08-20       Impact factor: 44.544

3.  Preoperative chemoradiation in fixed distal rectal cancer: dose time factors for pathological complete response.

Authors:  M Mohiuddin; W F Regine; W J John; P F Hagihara; P C McGrath; D E Kenady; G Marks
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-03-01       Impact factor: 7.038

4.  The magnetic resonance imaging-based approach for identification of high-risk patients with upper rectal cancer.

Authors:  Jee Suk Chang; Youngin Lee; Joon Seok Lim; Nam Kyu Kim; Seung Hyuk Baik; Byung So Min; Hyuk Huh; Woong Sub Koom
Journal:  Ann Surg       Date:  2014-08       Impact factor: 12.969

5.  Selecting patients with locally advanced rectal cancer for neoadjuvant treatment strategies.

Authors:  Alice Dewdney; David Cunningham; Ian Chau
Journal:  Oncologist       Date:  2013-07-02

6.  Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial.

Authors:  A J Breugom; W van Gijn; E W Muller; Å Berglund; C B M van den Broek; T Fokstuen; H Gelderblom; E Kapiteijn; J W H Leer; C A M Marijnen; H Martijn; E Meershoek-Klein Kranenbarg; I D Nagtegaal; L Påhlman; C J A Punt; H Putter; A G H Roodvoets; H J T Rutten; W H Steup; B Glimelius; C J H van de Velde
Journal:  Ann Oncol       Date:  2014-12-05       Impact factor: 32.976

7.  Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04.

Authors:  Samuel Y Ngan; Bryan Burmeister; Richard J Fisher; Michael Solomon; David Goldstein; David Joseph; Stephen P Ackland; David Schache; Bev McClure; Sue-Anne McLachlan; Joseph McKendrick; Trevor Leong; Cris Hartopeanu; John Zalcberg; John Mackay
Journal:  J Clin Oncol       Date:  2012-09-24       Impact factor: 44.544

8.  Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01.

Authors:  B Fisher; N Wolmark; H Rockette; C Redmond; M Deutsch; D L Wickerham; E R Fisher; R Caplan; J Jones; H Lerner
Journal:  J Natl Cancer Inst       Date:  1988-03-02       Impact factor: 13.506

9.  Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.

Authors:  Yong Sang Hong; Byung-Ho Nam; Kyu-Pyo Kim; Jeong Eun Kim; Seong Joon Park; Young Suk Park; Joon Oh Park; Sun Young Kim; Tae-You Kim; Jee Hyun Kim; Joong Bae Ahn; Seok-Byung Lim; Chang Sik Yu; Jin Cheon Kim; Seong Hyeon Yun; Jong Hoon Kim; Jin-Hong Park; Hee Chul Park; Kyung Hae Jung; Tae Won Kim
Journal:  Lancet Oncol       Date:  2014-09-04       Impact factor: 41.316

10.  Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control.

Authors:  R Glynne-Jones; N Counsell; P Quirke; N Mortensen; A Maraveyas; H M Meadows; J Ledermann; D Sebag-Montefiore
Journal:  Ann Oncol       Date:  2014-04-08       Impact factor: 32.976

View more
  4 in total

1.  Gd-EOB-DTPA-enhanced MR findings in chemotherapy-induced sinusoidal obstruction syndrome in colorectal liver metastases.

Authors:  Ying Ding; Sheng-Xiang Rao; Wen-Tao Wang; Cai-Zhong Chen; Ren-Chen Li; Mengsu Zeng
Journal:  J Int Med Res       Date:  2020-06       Impact factor: 1.671

2.  Mutated DNA Damage Repair Pathways Are Prognostic and Chemosensitivity Markers for Resected Colorectal Cancer Liver Metastases.

Authors:  Kun Wang; Ming Liu; Hong-Wei Wang; Ke-Min Jin; Xiao-Luan Yan; Quan Bao; Da Xu; Li-Jun Wang; Wei Liu; Yan-Yan Wang; Juan Li; Li-Juan Liu; Xiao-Yu Zhang; Chun-He Yang; Ge Jin; Bao-Cai Xing
Journal:  Front Oncol       Date:  2021-03-31       Impact factor: 6.244

3.  Overall Survival Benefit in Rectal Cancer After Neoadjuvant Radiotherapy and Adjuvant Chemotherapy: A Propensity-Matched Population-Based Study.

Authors:  Zhiju Chen; Shaowei Li; Yehong Wang; Zhiming Fu; Ning Liu; Hao Wang; Xin Liu
Journal:  Front Oncol       Date:  2020-12-09       Impact factor: 6.244

4.  Critical reappraisal of neoadjuvant concurrent chemoradiotherapy for treatment of locally advanced colon cancer.

Authors:  Yen-Cheng Chen; Hsiang-Lin Tsai; Ching-Chun Li; Ching-Wen Huang; Tsung-Kun Chang; Wei-Chih Su; Po-Jung Chen; Tzu-Chieh Yin; Chun-Ming Huang; Jaw-Yuan Wang
Journal:  PLoS One       Date:  2021-11-02       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.